| Dr Sheila Dawn Washburn, APRN, DNP, FNP-C | |
|
350 N 300 E, Pleasant Grove, UT 84062-2332 | |
| (801) 319-5491 | |
| Not Available |
| Full Name | Dr Sheila Dawn Washburn |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 350 N 300 E, Pleasant Grove, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1265071138 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 5333589-4405 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sheila Dawn Washburn, APRN, DNP, FNP-C 350 N 300 E, Pleasant Grove, UT 84062-2332 Ph: (801) 319-5491 | Dr Sheila Dawn Washburn, APRN, DNP, FNP-C 350 N 300 E, Pleasant Grove, UT 84062-2332 Ph: (801) 319-5491 |
News Archive
Seattle Genetics, Inc. today announced that preliminary data from a phase I study of SGN-75 in relapsed and refractory non-Hodgkin lymphoma and metastatic renal cell carcinoma will be presented during a poster session at the 35th European Society for Medical Oncology (ESMO) Congress being held October 8-12, 2010 in Milan, Italy.
PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company's existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.
Solvay Pharmaceuticals and CV Therapeutics have announced that the U.S. Food and Drug Administration (FDA) has approved Aceon (perindopril erbumine) Tablets for the treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction (MI).
Al Jazeera's "Inside Story" on Friday examined whether funding and political will can keep pace with efforts to vaccinate every child worldwide. The 25-minute video program, "with presenter Shiulie Ghosh, discusses with guests: Kate Elder from Doctors Without Borders; Adel Mahmoud, a global health specialist at Princeton University, and former president of Merck Vaccines," Al Jazeera writes.
The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.
› Verified 5 days ago
Ann Shipley, CRNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 360 S 1300 W, Pleasant Grove, UT 84062 Phone: 385-440-1400 | |
Nichole Chalise Nelson, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1446 W Pleasant Grove Blvd, Pleasant Grove, UT 84062 Phone: -- | |
Rachel Maria Hogan, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1176 E 260 S, Pleasant Grove, UT 84062 Phone: 801-358-2137 | |
Monica Constanza Bruna, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-757-3511 | |
Carol Ann Graff, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1886 W 800 N, Pleasant Grove, UT 84062 Phone: 801-429-8000 | |
Ruth A Hooper, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 830 N 2000 W, Pleasant Grove, UT 84062 Phone: 801-756-3511 Fax: 801-756-1705 | |
Dr. Brianna Lastre, DNP, WHNP, CNM Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1446 W Pleasant Grove Blvd., Pleasant Grove, UT 84062 Phone: 801-785-5100 |